2009 – present
The AFTD Postdoctoral Fellowship fosters basic, translational, clinical and/or epidemiological FTD research by an outstanding scientist at the beginning of his/her career. An individual with a Ph.D., M.D. or M.D./PhD. at an academic facility, teaching hospital, or research institution in the U.S. or Canada who will be in the first, second, or third year of his/her postdoctoral training at the start of the fellowship term is eligible to apply.
2013-2015 Postdoctoral Fellow
M. Catarina Silva, Ph.D.
Massachusetts General Hospital, Boston, Massachusetts
iPS cell development for FTD research
2011-2013 Postdoctoral Fellow
Alexandra Nicholson, Ph.D.
Mayo Clinic, Jacksonville, Florida
Genetic risk factors for FTD
2009 Postdoctoral Fellow
Todd Cohen, Ph.D.
Center for Neurodegenerative Research at the University of Pennsylvania, Philadelphia
Cell biology of TDP-43
2007 – present
AFTD has formed a partnership with the Alzheimer’s Drug Discovery Foundation (ADDF) of New York to fund the first ever grants for FTD drug discovery. The concept behind this funding program is to bridge the “gap” that exists for most rare diseases between basic research in the laboratory, where the goal is to understand the fundamental biological processes that have gone awry, and clinical testing of a potential drug. The gap in between these two steps yawns wide for rare diseases, because the potential market for any new drug isn’t deemed large enough to warrant investment on the part of the pharmaceutical companies (the source of the vast majority of dollars spent on drug development). For more information and a list of the grants the AFTD/ADDF have funded through this program, click here .
2005 – present
AFTD provides support for basic and clinical research in frontotemporal degeneration. Proposals are designed for generating preliminary data toward larger grant application to the NIH or other public or private agencies concerned with this important medical and social problem.
2013 Pilot Grant
Emily Rogalski, Ph.D.
Northwestern University, Cognitive Neurology and Alzheimer’s Disease Center
Internet-based speech therapy: Improving quality of life and access to care
2011 Pilot Grants
Fenghua Hu, Ph.D.
Cornell University, Department of Molecular Biology and Genetics, Cornell, New York
Signaling mechanisms of progranulin
2010 Pilot Grants
Stephanie Consentino, Ph.D. and Edward Huey, Ph.D.
Columbia University Medical Center, Department of Neurology, New York, New York
Cognitive and behavioral evaluations in offspring of MAPT mutation patients
Stephen Strittmatter, M.D., Ph.D.
Yale School of Medicine, New Haven, Connecticut
Molecule identification related to progranulin
2009 Pilot Grants
$120,000 (funded by AFTD in partnership with ADDF)
Manuela Neumann, M.D.
Institute of Neuropathology at the University of Zurich, Switzerland
Specific molecules that control TDP-43 phosphorylation
John Van Swieten, Ph.D.
Erasmus Medical Center Rotterdam, The Netherlands
Resting-State functional MRI in presymptomatic mutation carriers of MAPT or PGRN mutation
2008 Pilot Grants
Rosa Rademakers, Ph.D.
Mayo Clinic, Jacksonville, FL
MicroRNA dysregulation in frontotemporal lobar degeneration
Mark Gluck, Ph.D. & Murray Grossman, M.D.
Rutgers University & University of Pennsylvania
Insensitivity to Negative (Penalizing) Feedback for Inappropriate Behaviors in FTD Linked to Orbito-Frontal Dysfunction.
2007 Pilot Grants
J. Paul Taylor, M.D.
University of Pennsylvania School of Medicine
Assessing the molecular genetics of TDP-43-related neurodegeneration using a Drosophila model
Marc Cruts, Ph.D.
University of Antwerp
Gene identification in a novel Mendelian FTLD-MND locus
2006 Pilot Grants
Blair Levitt, M.D. & Ian Mackenzie, M.D.
University of British Columbia
Generation of a Mouse Model of Familial FTD Caused by Progranulin Mutations
2005 Pilot Grants
Eileen Bigio, M.D.
Northwestern University Feinberg School of Medicine
To study the ubiquinated proteins that are found in the “inclusions” that characterize brain cells in FTLD-MND